Bohgaki T, Atsumi T, Koike T.	Development of multiple autoimmune diseases after CD34+-selected autologous hematopoietic stem cell transplantation in a patient with systemic sclerosis.	N Engl J Med	357	2734-6	2007
Zhang MC, Mori S, Date F, Furukawa H, Ono M.	A non-MHC locus determines tissue-specificity in the pathogenic process underlying synovial proliferation in a mouse arthropathy model.	Ann Rheum Dis	66	242-245	2007
Misu N, Zhang MC, Mori S, Miyazaki T, Furukawa H, Sasaki T, Nose M, Ono M.	Autosomal loci associated with sex–related difference in the development of autoimmune phenotypes in a lupus model.	Eur J Immunol	37	2787-96	2007
Nakatani K, Qu WM, Zhang MC, Fujii H, Furukawa H, Miyazaki T, Iwano M, Saito Y, Nose M, Ono M.	A genetic locus controlling aging-sensitive regression of B lymphopoiesis in an autoimmune-prone MRL/lpr strain of mice.	Scand J Immunol	66	654-61	2007
Oka Y, Kameoka J, Hirabayashi Y, Takahashi R, Ishii T, Sasaki T, Harigae H.	Reversible Bone Marrow Dysplasia in Patients with Systemic Lupus Erythematosus.	Internal Medicine		in press	2008
Hirabayashi Y, Oka Y, Tada M, Takahashi R, Ishii T.	A potential trigger of nephritogenic anti-DNA antibodies in lupus nephritis.	Ann N Y Acad Sci	1108	92-95	2007
Oka Y, Hirabayashi Y, Ishii T, Takahashi R, Sasaki T.	A monoclonal antibody against human homocysteine-induced endoplasmic reticulum protein (Herp): a useful tool for evaluating endoplasmic reticulum stress.	Tohoku J Exp Med	212	431-37	2007
Kudoh K, Shibata C, Funayama Y, Fukushima K, Takahashi K, Ogawa H, Sagami Y, Hirabayashi Y, Moriya T, Sasaki I.	Gastrojejunostomy and duodenojejunostomy for megaduodenum in systemic sclerosis sine scleroderma: report of a case.	Dig Dis Sci	52	2257-60	2007
岡友美子, 平林泰彦	ストレス蛋白と抗DNA抗体産生	臨床免疫・アレルギー科	47	517-22	2007
Kamata Y, Takahashi Y, Iwamoto M, Matsui K, Murakami T, Muroi K, Ikeda U, Shimada K, Yoshio T, Okazaki H and Minota S	Local implantation of autologous mononuclear cells from bone marrow and peripheral blood for treatment of ischaemic digits in patients with connective tissue diseases.	Rheumatology	46	882-84	2007
岡崎 仁昭	リウマチ・膠原病患者の貧血の診かた	治療 89		2495-98	2007
岡崎 仁昭	リウマチ性疾患に対するスタチンの効果とその機序分子リウマチ	分子リウマチ	4	73-79	2007
岡崎 仁昭	頻度の高い症状、関節痛	治療薬・治療指針ポケットマニュアル 2007		96-100	2007
岡崎 仁昭	免疫・アレルギー疾患、関節リウマチ	治療薬・治療指針ポケットマニュアル 2007		461-65	2007
岡崎 仁昭	免疫・アレルギー疾患、全身性エリテマトーデスとその合併症	治療薬・治療指針ポケットマニュアル 2007		466-68	2007

岡崎 仁昭	諸科にわたって使われる薬剤、消炎・鎮痛薬	治療薬・治療指針ポケットマニュアル2007		676-87	2007
岡崎 仁昭	第2章 アレルギー・免疫疾患の主な症状。アレルギー・免疫疾患の診断。新体系 看護学全集22 成人看護学9 感染症アレルギー・免疫膠原病	メヂカルフレンド社		141-46	2007
岡崎 仁昭	第3章 アレルギー・免疫疾患の診断。新体系 看護学全集22 成人看護学9 感染症アレルギー・免疫膠原病	メヂカルフレンド社		147-56	2007
岡崎 仁昭	第4章 アレルギー・免疫疾患の主な治療法。新体系 看護学全集22 成人看護学9 感染症アレルギー・免疫膠原病	メヂカルフレンド社		157-62	2007
岡崎 仁昭	第5章 主なアレルギー・免疫疾患。新体系 看護学全集22 成人看護学9 感染症アレルギー・免疫膠原病	メヂカルフレンド社		163-83	2007
Iwanami K, Matsumoto I, Watanabe Y, Mihara M, Ohsugi Y, Mamura M, Goto D, Ito S, Tsutsumi A, Kishimoto T, Sumida T	Crucial role of IL-6/IL-17 cytokine axis in the induction of arthritis by glucose-6-phosphate-isomerase.	Arthritis Rheum		in press	
Kohno M, Tsutsumi A, Matsui H, Sugihara M, Suzuki T, Mamura M, Goto D, Matsumoto I, Ito S, Suguro T, Sumida T	Interleukin 17 gene expression in patients with rheumatoid arthritis	Mod Rheumatol		in press	
Ishii W, Ito S, Kondo Y, Tsuboi H, Mamura M, Goto D, Matsumoto I, Tsutsumi A, Okoshi Y, Hasegawa Y, Kojima H, Sakashita S, Aita K, Noguchi M, Sumida T	Intravascular large B-cell lymphoma with acute abdomen as a presenting symptom in a patient with systemic lupus erythematosus.	J Clin Oncol		in press	
伊藤 聡	Laser microdissection法による疾患発症関連分子解析の試み	分子リウマチ	4	63-67	2007
Kobayashi T, Ito S, Yasuda K, Kuroda T, Yamamoto K, Sugita N, Tai H, Narita I, Gejyo F, Yoshie H	The Combined Genotypes of Stimulatory and Inhibitory Fcγ Receptor Associated with Systemic Lupus Erythematosus and Periodontitis in Japanese	J Periodontology	78	467-74	2007
Kuroda T, Hirose S, Tanabe N, Sato H, Nakatsue T, Ajiro J, Wada Y, Murakami S, Hasegawa H, Ito S, Sakatsume M, Nakano M, Gejyo F	Mizoribine therapy for patients with lupus nephritis: the association between peak mizoribine concentration and clinical efficacy	Mod Rheumatol	17	206-12	2007
Enami T, Suzuki T, Ito S, Yoshimi A, Sugihara M, Mamura M, Hayashi T,Goto D, Matsumoto I, Tsutsumi A, Sumida T	Successful treatment of refractory thrombotic thrombocytopenic purpura with cyclosporine and corticosteroids in a patient with systemic lupus erythematosus and antibodies to ADAMTS13	Intern Med	46	1033-37	2007
Yokota K, Miyoshi F, Miyazaki T, Sato K, Yoshida Y, Asanuma Y, Akiyama Y, Mimura T.	High Concentration Simvastatin Induces Apoptosis in Fibroblast-like Synoviocytes from Patients with Rheumatoid Arthritis.	J Rheumatol.	35	193-200	2008 Feb
Kanda H, Yokota K, Kohno C, Sawada T, Sato K, Yamaguchi M, Komagata Y, Shimada K, Yamamoto K, Mimura T.	Effects of low-dosage simvastatin on rheumatoid arthritis through reduction of Th1/Th2 and CD4/CD8 ratios.	Mod. Rheumatol.	17	364-8	2007
Tsuzaka K, Itami Y, Kumazawa C, Suzuki M, Setoyama Y, Yoshimoto K, Suzuki K, Abe T, and Takeuchi T.	The conservative sequences in 3'UTR of TCRz mRNA regulate the production of TCRz and TCR/CD3 complex in SLE T cells.	BBRC	367	311-17	2008

Tsuzaka K, Matsumoto Y, Sasaki Y, Abe T, Tsubota K, and Takeuchi T.	Down-regulation of Fas-ligand mRNA Shogren' syndrome patients with enlarged exocrine glands.	Autoimmunity	40	497-502	2007
Ogawa H, Kameda H, Nagasawa H, Sekiguchi N, Takei H, Tsuzaka K, Amano K, and Takeuchi T.	Prospective study of low dose cyclosporine A in patients with refractory lupus nephritis.	Mod Rheum	17	92-97	2007
Tanaka Y, Yamamoto K, Takeuchi T, Nishimoto N, Miyasaka N, Sumida T, Shima Y, Takada K, Matsumoto I, Saito K, and Koike T.	A muticenter phase I/II trial of rituximab for refractory systemic lupus erythematosus.	Mod Rheum	17	191-97	2007
Kameda H, and Takeuchi T.	Platelet-Derived Growth Factor as a Therapeutic Target for systemic autoimmune diseases.	Drug Target Insight	2	1-9	2007
Suzuki K, Takei H, Kameda H, Nagasawa H, Sekiguchi N, Nishi E, Ogawa H, Tsuzaka K, Amano K, Takeuchi T.	Efficacy and Safety of Tacrolimus in Patients with rheumatoid arthritis in clinical practice: Significant role of blood concentration measurement for preventing severe adverse events.	Arthritis Rheum	S 35	CRC03	2007
高橋裕子、森口正人、住永佳久、長汐千秋、狩野俊和、鈴木暁岳、国松淳和、浅尾りん、山下裕之、伊藤健司、三森明夫、	Segmental arterial mediolysisの一例	日臨免会誌	30	193-97	2007
Nakajima K, Itoh1,K, Nagatani K, Okawa-Takatsuji M, Fujii T, Kuroki H, Katsuragawa Y, Aotsuka S, Mimori A	Expressionof BAFF and BAFF-R in the synovial tissue of patients with rheumatoid arthritis.	Scand J Rheumatol	36	365–72	2007
Nagatani K, Itoh K, Nakajima K, Kuroki H, Katsuragawa Y, Mochizuki, M Aotsuka S, Mimori A	Rheumatoid arthritis fibroblast-like synoviocytes express BCMA and are stimulated by APRIL.	Arthritis Rheum	56	3554-3563	2007
Okawa-Takatsuji M, Nagatani K, Nakajima K, Itoh K, Kano T, Nagashio C, Takahashi Y, Aotsuka S, Mimori A	A: Recruitment of immature neutrophils in peripheral blood following leukocytapheresis therapy for rheumatoid arthritis.	J Clin Apheresis	22	323-29	2007
Soejima M, Sugiura T, Kawaguchi Y, Kawamoto M, Katsumata Y, Takagi K, Nakajim A, MitamuraT, Mimori A, Hara M, and Kamatani N	Association of the diplotype configuration at the N-acetyltransferase 2 gene with adverse evnts with co-trioxazole in Japanese patients with systemic lupus erythematosus.	Arthritis Res Ther	9	R23	2007
Sato, S., Kuwana, M., and Hirakata, M.	Clinical characteristics of Japanese patients with anti-OJ (anti-Isoleucyl-tRNA Synthetase) autoantibodies.	Rheumatology	46	842-45	2007
Hirakata, M., Suwa, A., Takada, T., Sato, S., Nagai, S., Genth, E., Song, Y.W., Mimori, T., and Targoff, I.N.	Clinical and immunogenetic features of patients with autoantibodies to asparaginyl-transfer RNA synthetase.	Arthritis Rheum.	56	1295-303	2007
諏訪昭, 長谷川直樹, 平形道人, 齋藤栄子, 若林孝幸, 鈴木康夫	結核感染の新しい診断法: 全血インターフェロンγ応答測定法のリウマチ性疾患への応用	リウマチ科	37	191-96	2007
平形道人, 金子祐子	診断ピットフォール-症例から学ぶ-IV膠原病/筋痛	内科	99	1293-300	2007
平形道人	多発性筋炎・皮膚筋炎における自己抗体と発症機序	分子リウマチ	4	69-76	2007

平形道人	抗アミノアシルtRNA合成酵素抗体とその臨床的意義	リウマチ科	38	478-85	2007
白井悠一郎, 小泉加奈子, 小川理絵, 鈴木貴博, 小井戸則彦, 大曽根康夫, 秋月哲史, 高田哲也, 平形道人, 石原傳幸	抗signal recognition particle (SRP)抗体が検出されたステロイド療法抵抗性多発性筋炎の一例	日本内科学会雑誌	96	2522-24	2007
金子祐子, 平形道人	多発性筋炎に対するタクロリムスの効果	リウマチ科	38	556-60	2007
平形道人	多発性筋炎・皮膚筋炎における自己抗体とその臨床免疫学的意義	日本臨床免疫学会雑誌	30	444-54	2007
Takada K, J Kishi, N Miyasaka.	Step-up versus primary intensive approach to the treatment of interstitial pneumonia associated with dermatomyositis/polymyositis: a retrospective study.	Mod Rheumatol	17	123-30	2007
Nakano S, Morimoto S, Suzuki J, Nozawa K, Amano H, Tokano Y, Takasaki Y	Role of pathogenic auto-antibody production by Toll-like receptor 9 of B cells in active systemic lupus erythematosus.	Rheumatology (Oxford)	47	145-49	2008
Watanabe T, Suzuki J, Mitsuo A, Nakano S, Tamayama Y, Katagiri A, Amano H, Morimoto S, Tokano Y, Takasaki Y.	Striking alteration of some populations of T/B cells in systemic lupus erythematosus: relationship to expression of CD62L or some chemokine receptors.	Lupus.	17	26-33	2008
Amano H, Furuhata N, Tamura N, Tokano Y, Takasaki Y.	Hypocomplementemic Urticarial Vasculitis with Jaccoud's Arthropathy and Valvular Heart Disease (case report and review of the literature)	Lupus		in press	2008
Nakano S, Morimoto S, Suzuki J, Mitsuo A, Nakiri Y, Katagiri A, Nozawa K, Amano H, Tokano Y, Hashimoto H, Takasaki Y.	Down-regulation of CD72 and increased surface IgG on B cells in patients with lupus nephritis.	Autoimmunity.	40	9-15	2007
Morimoto S, Nakano S, Watanabe T, Tamayama Y, Mitsuo A, Nakiri Y, Suzuki J,Nozawa K, Amano H, Tokano Y, Kobata T, Takasaki Y.	Expression of B-cell activating factor of the tumour necrosis factor family (BAFF) in T cells in active systemic lupus erythematosus: the role of BAFF in T cell-dependent B cell pathogenic autoantibody production	Rheumatology	46	1083-86	2007
Nakiri Y, Minowa K, Suzuki J, Mitsuo A, Amano H, Morimoto S, Tokano Y, Takasaki Y.	Expression of CD22 on peripheral B cells in patients with rheumatoid arthritis:relation to CD5-positive B cells.	Clin Rheumatol.	26	1721-23	2007
Tsukamoto H, Ohtsuji M, Shiroiwa W, Lin Q, Nakamura K, Tsurui H, Jiang Y, Sudo K, Nishimura H, Shirai T, and Hirose S.	Aberrant genetic control of invariant TCR-bearing NKT cell function in New Zealand mouse strains: possible involvement in SLE pathogenesis.	J. Immunol.		in press	2008
Nakamura K, Hirai H, Torashima T, Miyazaki T, Tsurui H, Xiu Y, Ohtsuji M, Qing Shun Lin Q, Tsukamoto K, Nishimura H, Ono M, Watanabe M Hirose S.	CD3 and IgG Fc receptor regulate cerebellar functions.	Mol. Cell. Biol.	27	5128-34	2007
林 青順、広瀬幸子	全身性自己免疫疾患とFcgレセプターによる免疫反応の正と負の調節	臨床免疫・アレルギー科	47	545-550	2007
Yamada, R, Yamamoto, K.	Mechanisms of disease: genetics of rheumatoid arthritis--ethnic differences in disease-associated genes.	Nat Clin Pract Rheumatol	3	644-50	2007

Suzuki, A., Yamada, R, Yamamoto, K.	Citrullination by peptidylarginine deiminase in rheumatoid arthritis.	Ann N Y Acad Sci	1108	323-39	2007
Yamada R, Matsuda.F	A novel method to express SNP-based genetic heterogeneity, Ψ, and its use to measure linkage disequilibrium for multiple SNPs, Dg, and to estimate absolute maximum of haplotype frequency.	Genetic Epidemiology	31	709-26	2007
Toba T, Murata K, Nakanishi K, Takahashi B, Takemoto N, Akabane M, Nakatsuka T, Imajo S, Yamamura T, Miyake S and Annoura H.	Minimum structure requirement of immunomodulatory glycolipids for predominant Th2 cytokine induction and the discovery of non-linear phytosphingosine analogs.	Bioorganic Med.Chem.Let.	17	2781-4	2007
Kaieda S, Tomi C, Oki S, Yamamura T and Miyake S.	Activation of iNKT cells by synthetic glycolipid ligands suppresses autoantibody-induced arthritis.	Arthritis Rheum.	56	18365-45	2007
Sakuishi K, Oki S, Araki M, Porcelli SA, Miyake S, YamamuramT.	Invariant NKT cells biased for IL-5 production act as crucial regulators of inflammation.	J.Immunol.	179	3452-62	2007
Ambrosino E, Terabe M, Halder RC, Peng J, Takaku S, Miyake S, Yamamura T, Kumar V, Berzofskky.	Cross-regulation between Type I and Type II NKT cells in regulating turmor immunity: A new immunoregulatory axis.	J.Immunol.	179	5126-36	2007
Oki S, Miake S.	Invariant Natural Killer (iNKT) cells in asthma: A novel insight into the pathogenesis of asthma and the therapeutic implication of glycolipid ligands for allergic diseases.	Allergol Int.	56	7-14	2007
Yamamura T, Sakuishi K, Illes Z and Miyake S.	Understanding the behavior of invariant NKT cells in autoimmune diseases.	. J. Neuroimmunol.	1914	8-15	2007
Miyake S and Yamamura T.	Glycolipid autoimmunity	Int. Rev. Immunol.	26	73-94	2007
Okunuki, Y. Y. Usui, M. Takeuchi, T. Kezuka, T. Hattori, K. Masuko, H. Nakamura, K. Yudoh, M. Usui, K. Nishioka, and T. Kato	Proteomic surveillance of autoimmunity in Behcet's disease with uveitis: Selenium binding protein is a novel autoantigen in Behcet's disease.	Exp Eye Res.	84	823-31	2007
Xiang Y, Matsui T, Matsuo K, Shimada K, Tohma S, Nakamura H, Masuko K, Yudoh K, Nishioka K, Kato T	Comprehensive investigation of disease-specific short peptides in sera from patients with systemic sclerosis: Complement C3f-des-arginine, detected predominantly in systemic sclerosis sera, enhances proliferation of vascular endothelial cells.	Arthritis Rheum.	56	2018-30	2007
Nakamura, H. K. Masuko, K. Yudoh, T. Kato, K. Nishioka, T. Sugihara and M. Beppu.	Positron emission tomography with (18)F-FDG in osteoarthritic knee.	Osteoarthritis Cartilage	15	673-81	2007
Yudoh K., Shishido K., Murayama H., Yano M., Matsubayashi K., Takada H., Nakamura H., Masuko K., Kato T.	Water-soluble fullerene (C60) prevents degeneration of articular cartilage in osteoarthritis (OA): C60 downregulates catabolic activity of chondrocytes and inhibits degeneration of articular cartilage during the development of OA.	Arthritis Rheum.	56	3307-18	2007
Yamakawa K, Yoshida K, Nishikawa H, Kato T, Iwamoto T.	Comparative analysis of interindividual variations in the seminal plasma proteome of fertile men with identification of potential markers for azoospermia in infertile patien.	J Andrology	28	858-65	2007
Masuko K, Murata M, Xiang Y, Nakamura H, Yudoh K, Nishioka K, Beppu M, Kato T.	Tryptase enhances release of vascular endothelial growth factor from human osteoarthritic chondrocytes.	Clin Exp Rheumatol.	25	860-65	2007

Ishizaki M, Sasada T, Kunitomi A, Konaka Y, Yagita M, Gunji S, Kanai M, Nishimoto N, Takabayashi A.	Uneventful spelenectomy and cholecystectomy in a patient treated with anti-interleukin-6 receptor antibody therapy.	Langenbecks Arch Surg		[Epub ahead of print]	2007
Nishimoto N, Kishimoto T.	Humanized Antihuman IL-6 Receptor Antibody, Tocilizumab.	Handbook of Experimental Pharmacology		151-60	2007
Nishimoto N, Kishimoto T.	Update on interleukin-6	Contemporary Targeted Therapies in Rheumatology		149-58	2007
Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Murata N, van der Heijde D, Kishimoto T.	Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor(SAMURAI):evidence of clinical and radiographic benefit from an X ray reader-blinded randomised controlled trial of tocilizumab.	Ann Rheum Dis	66	1162-67	2007
Tsujimura S, Saito K, Nawata M, Nakayamada S, Tanaka Y.	Overcoming drug resistance induced by P-glycoprotein on lymphocytes in patients with refractory rheumatoid arthritis.	Ann Rheum Dis.		in press	
Takeuchi T, Tatsuki T, Nogami N, Ishiguro N, Tanaka Y, Yamanaka H, Harigai M, Ryu J, Inoue K, Kondo H, Inokuma S, Kamatani N, Ochi T, Koike T.	Post-marketing surveillance of the safety profile of infliximab in 5,000 Japanese patients with rheumatoid arthritis.	Ann Rheum Dis.		in press	
Mizobe T, Tsukada J, Higashi T, Mouri F, Matsuura A, Tanikawa R, Minami Y, Yoshida Y, Tanaka Y.	Constitutive association of MyD88 to IRAK in HTLV-I-transformed T cells.	Exp Hematology.		in press	
Mouri F, Tsukada J, Mizobe T, Higashi T, Yoshida Y, Minami Y, Izumi H, Kominato Y, Kohno K, Tanaka Y.	Intracellular HMGB1 transactivates the human IL-1b gene promoter through association with an Ets transcription factor PU.1.	Eur J Haematol.		in press	
Tanaka Y, Takeuchi T, Inoue E, Saito K, Sekiguchi N, Sato E, Nawata M, Kameda H, Iwata S, Amano K, Yamanaka H.	Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: One-year clinical outcomes (RECONFIRM-2)	Mod Rheumatol.		in press	
Tanikawa R, Okada Y, Nakano K, Tanikawa T, Hirashima M, Yamauchi A, Hosokawa R, Tanaka Y.	Interaction of galectin-9 with lipid rafts induces osteoblast proliferation through the c-Src/ERK signaling pathway.	J Bone Miner Res.		in press	
Nishida K, Okada Y, Nawata M, Saito K, Tanaka Y.	Induction of hyperadiponectinemia following long-term treatment of patients with rheumatoid arthritis with infliximab (IFX), an anti-TNF-alpha antibody.	Endocrine J.		in press	
Higashi T, Wakui M, Nakano K, Hashimoto K, Takagi R, Tanaka Y, Matsushita S.	Evaluation of adjuvant activities using human antigen presenting cells in vitro.	Allergology Int.		in press	
Tanaka Y.	B cell-targeting therapy using anti-CD20 antibody rituximab in inflammatory autoimmune diseases.	Internal Medicine.		in press	
Nakano K, Saito K, Mine S,Matsushida S, Tanaka Y.	CD44 signaling up-regulates Fas Ligand expression on T cells leading to activation-induced cell death.	Apoptosis.	12	45-54	2007
Yamanaka H, Tanaka Y, Sekiguchi N, Inoue E, Saito K, Kameda H, Iikuni N, Nawata M, Amano K, Shinozaki M, Takeuchi T.	Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM)	Mod Rheumatol.	17	28-32	2007

Hirai F, Nakayamada S, Okada Y, Saito K, Kurose H, Mogami A, Tanaka Y.	Small GTPase Rho signaling is involved in β1 integrin-mediated up-regulation of intercellular adhesion molecule 1 and receptor activator of nuclear factor κB ligand on osteoblasts and osteoclast maturation.	Biochem Biophy Res Commun.	356	279-85	2007
Tokunaga M, Saito K, Kawabata D, Imura Y, Fujii T, Nakayamada S, Tsujimura S, Nawata M, Iwata S, Azuma T, Mimori T, Tanaka Y.	Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system.	Ann Rheum Dis.	66	470-75	2007
Nakano K, Okada Y, Saito K, Tanikawa R, Sawamukai N, Sasaguri Y, Kohro T, Wada Y, Kodama M, Tanaka Y.	Rheumatoid synovial endothelial cells produce macrophage-colony stimulating factor leading to osteoclastogenesis in rheumatoid arthritis.	Rheumatology.	46	597-603	2007
Nakayamada S, Saito K, Nakano K, Tanaka Y.	β1 integrin transduces an activation signal in T cells of patients with systemic lupus erythematosus.	Arthritis Rheum.	56	1559-68	2007
Tabata T, Mine S, Okada Y, Tanaka Y.	Low molecular weight hyaluronan increases the uptaking of oxidized LDL into monocytes.	Endocrine J.	54	685-92	2007
Sawamukai N, Saito K, Yamaoka K, Nakayamada S, Ra C, Tanaka Y.	Leflunomide inhibits PDK1/Akt pathway and induces apoptosis of human mast cells.	J Immunol.	179	6479-84	2007
Mera T, Fujihara H, Sato J, Kawasaki M, Hashimoto H, Saito T, Shibata M, Onaka T, Tanaka Y, Oka T, Tsuji S, Ueta Y.	Downregulation of prolactin-releasing peptide gene expression in the hypothalamus and brasnstem of diabetic rats.	Peptides.	28	1596-604	2007
Nakayamada S, Saito K, Umehara H, Ogawa N, Sumida T, Ito S, Minota S, Nara H, Kondo H, Okada J, Mimori T, Yoshifuji H, Sano H, Hashimoto N, Sugai S, Tanaka Y.	Efficacy and safety of mizoribine for the treatment of Sjö gren's syndrome — a multicenter open-label clinical trial.	Mod Rheumatol.	17	464-69	2007
Eguchi K, Saito K, Kondo M, Hidaka T, Ueki Y, Tanaka Y.	Enhanced effect of high-dose leukocytapheresis using a large filter in rheumatoid arthritis.	Mod Rheumatol.	17	481-85	2007
Yamaoka K, Saito K, Nakayamada S, Yamamoto M, Tanaka Y.	Clinical images: Takayasu's arteritis.	Arthritis Rheum.	56	2466	2007
Kishikawa H, Okada Y, Kawahara T, Saito K, Tanaka Y.	A case of blue rubber nevus syndrome treated by etidronate.	J Bone Miner Metabolism.	25	138-41	2007
Yamaoka K, Saito K, Hanami K, Nakayamada S, Nawata M, Iwata S, Azuma T, Tanaka Y.	A case of life-threatening refractory polychondritis successfully treated with combined intensive immunosuppressive therapy with methotrexate.	Mod Rheumatol .	17	144-47	2007
Mori H, Okada Y, Tanaka Y.	Etidronate for the treamtment of progressive tumoral calcinosis in hemodialysis patients.	Internal Medicine.	46	1485-86	2007
Tsujimura S, Saito K, Nakayamada S, Tanaka Y.	Relevance of multidrug resistance 1 and P-glycoprotein to drug resistance in patients with systemic lupus erythematosus.	Histol Histopathol.	22	465-468	2007
Mine S, Tanaka Y.	Lansoprazole-induced improvement of esophageal submucosal injury.	J Clin Biochem Nutr.	41	92-96	2007

江口 勝美、蒲池 誠、折口 智樹、中村 秀樹、井田 弘明、右田 清志	リウマチ(膠原病)·アレルギー学	日本医事新報	4327	64-73	2008
Kamachi M, Aramaki T, Tanimura S, Ichinose K, Fujikawa K, Iwamoto N, Yoshizaki A, Ida H, KawakaminA, Kohno M, Eguchi K.	Activation of protein phosphatase causes alternative splicing of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL):potential effect on immune surveillance.	Biochem BiophysRes Commun.	360	280-85	2007
Iwanaga N, Kamachi M, Fujikawa K, Aramaki T, Izumi Y, Arima K, Tamai M, Arakate K, Nakamura H, Origuchi T, Ida H,Kawakami A, Taguchi T, Eguchi K.	Membranous glomerulonephritis and non-Hodgkin's lymphoma in a patents with primary Sjögren's syndrome.	Internal Med.	46	191-94	2007
蒲池 誠、江口 勝美	細胞内シグナル伝達を介したalternative splicingの誘導:その生物学的意義と制御メカニズム	日本炎症再生医学会雑誌	27	575-78	2007
蒲池 誠、江口 勝美	SR蛋白質のリン酸化、脱リン酸化とalternative splicing制御ーSLE(全身性エリテマトーデス)における病態的意義と新規治療法への展望	リウマチ科	38	109-112	2007
Huang M, Ida H, Arima K, Nakamura H, Atamaki T, Fujikawa K, Tamai M, Kamachi M, Kawakami A, Yamasaki H, Eguchi K.	La autoantigen translocates to cytoplasm after cleavage during gramzyme B-mediated cytotoxity.	Life Science.	81	1461-66	2007
Kawakami A, Nakamura K, Tamai M, Nakamura H, Iwanaga N, Fujikawa K, Aramaki T, Arima K, Iwamoto N, Ichinose K, Kamachi M, Ida H, Origuchi T, Eguchi K.	Toll-like receptor in salivery glands from patients with Sjö gren's syndrome:functional analysis by human salivery gland cell line.	J Rheumatol.	34	1019-26	2007
Fujikawa K, Aratake K, Kawakami A, Aramaki T, Iwanaga N, Izumi Y, Arima K, Kamachi M, Tamai M, Huang M, Nakamura H, Nishiura Y, Origuchi T, Ida H, Eguchi K.	Successful treatment of refractory neuro-Behcet's disease with infliximab: a case repoet to show its efficacy by magnetic resonance imaging, transcranial magnetic stimulation and cytokine profile.	Ann Rheum Dis	66	136-37	2007

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名・出版地	頁	出版年
Atsumi T, Amengual O, Koike T.	Etiopathology of the Antiphosphospholipid syndrome	Sueishi K	Recent Advances in Thrombosis and Haemostasis	Springer Japan (Tokyo)	in press	
Amengual O, Atsumi T, Koike T.	Antiphospholipid antibodies and the Antiphosphospholip syndrome	Columbus F	New Research on Autoantibodie	Nova Science Publishers (New Yourk)	in press	
渥美達也	抗DNA抗体、抗リン脂質抗体	和田攻、大久保昭行、矢崎義雄、大内尉義	臨床検査ガイド2007-2008	文光堂、東京	665-7	2007
渥美達也	抗リン脂質抗体症候群と血栓症	高久史麿、溝口秀昭、坂田洋一、金倉譲、小島勢二	Annual Review 血液2007	中外医学社、東京	256-64	2007
渥美達也	抗リン脂質抗体症候群	杉本恒明、矢崎義雄総	内科学 第9版	朝倉書店、東京	1091-3	2007
伊藤健司、三森明夫	膠原病 セカンドオピニオン実践ガイド	和田攻ほか編	膠原病	文光堂、東京	422-32	2007
鈴木暁岳、三森明夫	発熱		診断ピットフォール一症例から学ぶ	南江堂、東京	1278-87	2007
三森明夫	全身性強皮症	杉本恒明、矢崎義男編	内科学	朝倉書店、東京	1076-79	2007
三森明夫、秋葉正文	関節リウマチ		今日の病態栄養療法	南江堂、東京	印刷中	2008
平形道人	多発性筋炎・皮膚筋炎.	泉 孝英 編集	ガイドライン 外来診療 (2008年版)	医学書院・東京	印刷中	
平形道人	好酸球性筋膜炎.	山口 徹, 北原光夫, 総編集	今日の治療指針 (2008年版)	医学書院・東京	629-30	2008
平形道人	多発性筋炎・皮膚筋炎.	井村裕夫 監修	わかりやすい内科学 第3版	文光堂・東京	395-401	2008
Miyake S , Yamamura T.	NKT cells and autoimmune diseases: unrabeling the complexity.	D.Branch Moody	Cur. Top. Microbiol. Immunol.	Spinger, New York	251-67	2007

Ⅳ.　研究成果の刊行物・別刷

IL-17B and IL-17C Are Associated with TNF-α Production and Contribute to the Exacerbation of Inflammatory Arthritis[1]

Yumi Yamaguchi,* Keishi Fujio,[2]* Hirofumi Shoda,* Akiko Okamoto,* Nelson H. Tsuno,† Koki Takahashi,† and Kazuhiko Yamamoto*

IL-17A is a T cell-derived proinflammatory cytokine that contributes to the pathogenesis of rheumatoid arthritis. Recently, six related molecules have been identified to form the IL-17 family, as follows: IL-17A, IL-17B, IL-17C, IL-17D, IL-17E, and IL-17F. Whereas IL-17A and IL-17F up-regulate IL-6 in synovial fibroblasts, IL-17B and IL-17C are reported to stimulate the release of TNF-α and IL-1β from the monocytic cell line, THP-1 cell. However, their detailed function remains to be elucidated. We report in this study the effects of IL-17 family on the collagen-induced arthritis (CIA) progression by T cell gene transfer and bone marrow chimeric mice. The mRNA expressions of IL-17 family (IL-17A, IL-17B, IL-17C, and IL-17F) and their receptor (IL-17R and IL-17Rh1) genes in the arthritic paws of CIA mice were elevated compared with controls. Although IL-17A and IL-17F were expressed in CD4$^+$ T cells, IL-17B and IL-17C were expressed in the cartilage and in various cell populations in the CIA arthritic paws, respectively. In vitro, IL-17A, IL-17B, IL-17C, and IL-17F induced TNF-α production in mouse peritoneal exudate cells. In vivo, adoptive transfer of IL-17B- and IL-17C-transduced CD4$^+$ T cells evidently exacerbated arthritis. Bone marrow chimeric mice of IL-17B and IL-17C exhibited elevated serum TNF-α concentration and the high arthritis score upon CIA induction. Moreover, neutralization of IL-17B significantly suppressed the progression of arthritis and bone destruction in CIA mice. Therefore, not only IL-17A, but also IL-17B and IL-17C play an important role in the pathogenesis of inflammatory arthritis. ***The Journal of Immunology,*** **2007, 179: 7128–7136.**

Interleukin-17A is a T cell-derived proinflammatory cytokine that is involved in the development of rheumatoid arthritis (RA).[3] IL-17A was originally named CTLA-8 after being cloned from activated T cells, and shares 57% homology to the protein encoded by the open reading frame 13 gene of the T lymphotropic herpesvirus saimiri (1). IL-17A is present at significant levels in the synovium and synovial fluid of patients with RA (2, 3). IL-17A is a potent inducer of various cytokines such as IL-1, TNF-α, and IL-6. T cell IL-17A stimulates the production of IL-1 and TNF-α from human PBMC-derived macrophages in vitro (4). IL-17A also enhances IL-1-mediated IL-6 production by RA synoviocytes in vitro as well as TNF-α-induced synthesis of IL-1, IL-6, and IL-8 (5, 6). These results indicate that IL-17A synergizes with IL-1 and TNF-α and contributes to inflammation of RA.

In in vivo studies, systemic as well as local overexpression of IL-17A in collagen-induced arthritis (CIA) has been shown to accelerate the onset of CIA and to aggravate the joint pathology (7). Moreover, treatment with anti-IL-17A Abs after the onset of CIA reduces the joint inflammation and histologic destruction of cartilage (8). IL-17A deficiency protects IL-1R antagonist-deficient mice from spontaneous development of destructive arthritis (9). Therefore, IL-17A plays a crucial role in the pathogenesis of arthritis through synergistic effects with IL-1 and TNF-α. However, IL-17A can directly induce joint destruction in an IL-1-independent manner and can bypass TNF-dependent arthritis (7, 10). This suggests that there is an IL-17A-dependent pathway to the destructive arthritis and anti-IL-17A cytokine therapy is an additional new antirheumatic strategy for RA besides anti-TNF/anti-IL-1 therapy.

Recently, the IL-17 family was determined to consist of six related molecules, as follows: IL-17A, IL-17B, IL-17C, IL-17D, IL-17E, and IL-17F. These molecules have a molecular mass of 20–30 kDa and consist of 163–202 aa that bear 20–50% homology to IL-17A, especially within the C-terminal region. They share four conserved cysteine residues that may participate in the formation of intermolecular disulfide linkages (11, 12). The different IL-17 family members seem to have very distinct expression patterns, suggesting distinct biological roles.

Interestingly, IL-17F has the highest homology with IL-17A and is also expressed by activated T cells in response to IL-23 stimulation (13–15). However, the precise effect of IL-17F on arthritis has not been clarified. In contrast to the restricted expression of IL-17A and IL-17F, IL-17B mRNA can be detected in a wide range of tissues, including the spinal cord, testis, stomach, small intestine, pancreas, prostate, and ovary (16, 17). It has been recently reported that IL-17B is highly expressed in chondrocytes

*Department of Allergy and Rheumatology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan; and †Department of Transfusion Medicine and Immunohematology, University of Tokyo, Tokyo, Japan

Received for publication April 12, 2007. Accepted for publication September 5, 2007.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

[1] This study was supported by Program and Project Grant funding from Japan Society for the Promotion of Science; Ministry of Health, Labour and Welfare; and Ministry of Education, Culture, Sports, Science and Technology.

[2] Address correspondence and reprint requests to Dr. Keishi Fujio, Department of Allergy and Rheumatology, Graduate School of Medicine, University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan. E-mail address: kfujio-tky@umin.ac.jp

[3] Abbreviations used in this paper: RA, rheumatoid arthritis; BCII, bovine type II collagen; BM, bone marrow; CIA, collagen-induced arthritis; mIL, murine IL; MMP, matrix metalloproteinase; PEC, peritoneal exudate cell; pMIG, murine stem cell virus/internal ribosome entry site/GFP.

that are located at the mid and deep zones of normal bovine articular cartilage (11). In contrast, IL-17C expression has been confined only to rare expression sequence tags in adult prostate and fetal kidney libraries (17). However, the cell sources of IL-17B and IL-17C have not been identified in the development of inflammatory arthritis.

A common feature of IL-17 family members is the induction of neutrophil migration. IL-17A and IL-17F both mobilize neutrophils partly through granulopoiesis and CXC chemokine induction (12). Intranasal administration of adenovirus expressing IL-17A, IL-17C, or IL-17F resulted in neutrophilia in the bronchoalveolar lavage (18). Moreover, i.p. injection of human rIL-17B caused marked neutrophil migration in normal mice (17). In contrast, the members can be divided into two groups according to the induction of cytokine production. Although IL-17A and IL-17F up-regulate IL-6 and IL-8 in human fibroblasts (19, 20), IL-17B and IL-17C are reported to stimulate the release of TNF-α and IL-1β from the monocytic cell line THP-1 (17). Taken together, these results indicate that IL-17 family members induce inflammatory cytokines not only through activated T cells, but also through activated monocytes/macrophages.

Based on the structural and functional similarities among IL-17 family members, we speculated that not only IL-17A, but also other IL-17 family members are involved in the pathogenesis of many inflammatory and autoimmune disorders, especially in the development of RA. We focused on IL-17A, IL-17B, IL-17C, and IL-17F, which can affect inflammatory cytokine production of fibroblasts and macrophages. Recently, IL-17C expression in synovial fluid mononuclear cells and PBMCs of RA patients was reported (21). However, the biological effect of IL-17 family members in arthritis has not been analyzed.

In the present study, we investigated the expression and effect of IL-17 family members in arthritis. In vitro, not only IL-17A, but also IL-17B and IL-17C induced the mRNA expression of inflammatory cytokines such as IL-1β, IL-6, and IL-23 in the *3T3* cell line and peritoneal exudate cells (PECs). The supernatant of the PECs stimulated with each IL-17 family member all increased TNF-α production significantly compared with controls. In vivo, $CD4^+$ T cells transduced with each of IL-17B, IL-17C, or IL-17F exacerbated CIA in mice to the same degree as $CD4^+$ T cells transduced with IL-17A. Mice reconstituted with bone marrow (BM) cells transduced with each of IL-17B, IL-17C, or IL-17F suffered from severe CIA. Moreover, neutralization of IL-17B significantly suppressed the progression of arthritis and bone destruction in CIA mice. Our results suggest that not only IL-17A, but also the other IL-17 family members (IL-17B, IL-17C, and IL-17F) are associated with inflammatory cytokines such as IL-1 and TNF-α and contribute to the exacerbation of autoimmune arthritis.

Materials and Methods

Animals

DBA/1J mice were purchased from Japan SLC. All mice were used at 6–8 wk of age. All animal experiments were conducted in accordance with the institutional and national guidelines.

Collagen-induced arthritis

CIA was induced, as described previously (22–24). In brief, bovine type II collagen (BCII) (Chondrex) was emulsified with an equal volume of CFA (Chondrex). DBA/1J mice were immunized intradermally at the base of the tail with 100 μg of BCII emulsified with CFA. On day 21, the mice were boosted by intradermal injection with 100 μg of BCII emulsified with IFA (Difco). The arthritis score was determined by erythema, swelling, or ankylosis per paw, as described previously (25, 26). The clinical arthritis score was defined as the sum of the scores of all four paws of each mouse.

Cytokines and cell lines

Recombinant murine IL (mIL)-17A, mIL-17B, mIL-17C, and mIL-17F were obtained from R&D Systems. The mouse fibroblast cell line *3T3* was obtained from American Type Culture Collection. This cell line was cultured with RPMI 1640 (Invitrogen Life Technologies) medium supplemented with 10% FCS, 2 mM γ-glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin, and 5×10^{-5} M 2-ME. Ba/F3 cells were maintained in RPMI 1640 medium supplemented with 10% FCS, 2 mM γ-glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin, and 1 ng/ml rmIL-3 (R&D Systems).

Murine PECs

Murine PECs were isolated after i.p. injection of 3 ml of 5% sterile fluid Brewer's thioglycolate broth (Sigma-Aldrich) into 8-wk-old DBA/1J mice (27). After culture of the PECs in a 6-well plate for 2 h, floating cells were removed by extensive washing, and attached cells were maintained in the medium described above for 3 days. More than 80% of the cultured cells were macrophages as determined by flow cytometric analysis of CD11b-positive cells. The following recombinant murine cytokines were added to the culture medium and incubated for 24 h: 50 ng/ml mIL-17A, mIL-17B, mIL-17C, or mIL-17F.

Preparation of retroviral constructs of mIL-17 family cDNAs

mIL-17A, mIL-17B, mIL-17C, and mIL-17F were isolated from the murine T lymphocyte cDNA library according to the reported nucleotide sequence from National Center for Biotechnology Information (mIL-17A NM_010552; mIL-17B NM_019508; mIL-17C NM_145834; mIL-17F NM_145856). The full-length fragments were subcloned into retrovirus vector murine stem cell virus/internal ribosome entry site/GFP (pMIG), as described previously (28).

Production of retroviral supernatants and retroviral transduction

Retroviral supernatants were obtained by transfection of pMIG carrying each of the IL-17 family genes into PLAT-E packaging cell lines using FuGENE 6 transfection reagent (Roche Diagnostic System), as described previously (29). For the detection of GFP-positive cells, we used an EPICS XL flow cytometer (Beckman Coulter).

Gene transduction to mouse splenocytes and adoptive transfer

Total splenocytes were cultured for 48 h in the presence of Con A (10 μg/ml) (Sigma-Aldrich) and mIL-2 (50 ng/ml) (R&D Systems). Retroviral gene transduction was performed, as described previously (30, 31). A $CD4^+$ T cell population was prepared by negative selection by MACS with anti-CD19 mAb, anti-CD11c mAb, and anti-CD8a mAb (BD Pharmingen). The gene-transduced $CD4^+$ T cells were suspended in PBS and injected i.v. (1×10^7) at 23 days after the first immunization of BCII.

BM precursor cell isolation, infection, and transfer

BM precursor cell isolation, retrovirus infection, and transfer were performed, as described previously (32). In brief, DBA/1J mice were treated with 5 mg/body 5-fluorouracil (Sigma-Aldrich) dissolved in PBS. After 5 days, BM cells were harvested and cultured with 50 ng/ml mIL-3, mIL-6, and murine stem cell factor (R&D Systems) for 48 h. Then the BM cells were spin infected with the retrovirus supernatants with 16 μg/ml polybrene (Sigma-Aldrich) for 90 min at 2400 rpm and 25°C. Recipient mice were treated by 700 rad of whole-body radiation and were injected with 1×10^6 of the BM cells i.v. Recipient mice were maintained for 6 wk until analysis or immunization.

RNA isolation, cDNA synthesis, and quantitative real-time PCR

RNA of the cells was extracted using an RNeasy Micro Kit and RNeasy Mini Kit (Qiagen). RNA from the tissues was isolated by the acid guanidinium thiocyanate-phenol-chloroform extraction method using ISOGEN (Nippon Gene). RNA was reverse transcribed to cDNA with random primers (Invitrogen Life Technologies) and Superscript III, according to the manufacturer's protocol (Invitrogen Life Technologies). To determine the cellular expression of each protein, quantitative real-time PCR analysis was performed using an iCycler (Bio-Rad). The PCR mixture consisted of 25 μl of SYBR Green Master Mix (Qiagen), 15 pmol of forward and reverse primers, and the cDNA samples, in a total volume of 50 μl. We calculated the quantitative PCR data with δ cycle threshold method, and relative RNA abundance was determined based on control β-actin abundance. To measure the relative efficiency,

amplifications were performed on the serial diluted cDNA samples using primers for the target and the reference (β-actin) genes. We made plots of the log cDNA dilution vs δ cycle threshold, and confirmed that the efficiencies of the target and the reference genes were similar because the absolute value of the slope was close to zero (data not shown) (33, 34). The primer pairs used in the quantitative real-time PCR were as follows: mouse IL-17A, sense 5′-GCTCCAGAAGGCCCTCAGA-3′, antisense 5′-AGCTTTCCCTCCGCATTGA-3′; mouse IL-17B, sense 5′-CGGTGCCTATGTTTGGGTTGC-3′, antisense 5′-GGGTTG GTGGTTGGCTCAGAA-3′; mouse IL-17C, sense 5′-CACAGATGAG AACCGCTACCC-3′, antisense 5′-GCGGATGAACTCGGTGTGGA A-3′; mouse IL-17F, sense 5′-CAACGCTGCATACAAAAATCA-3′, antisense 5′-TTAAGTGAGGCATTGGGAACA-3′; mouse IL-17R, sense 5′-CCACTCTGTAGCACCCCAATG-3′, antisense 5′-CCTGGA GATGTAGCCCTGGTC-3′; mouse IL-17Rh1, sense 5′-GCAAGGAA GGAGCACGAAGAC-3′, antisense 5′-CTCGGCGATTTTCTTTTTCT G-3′; mouse TNF-α, sense 5′-CATCTTCTCAAAATTCGAGTGACA A-3′, antisense 5′-TGGGAGTAGACAAGGTACAACCC-3′; mouse IL-1β, sense 5′-CAACCAACAAGTGATATTCTCCATG-3′, antisense 5′-GATCCACACTCTCCAGCTGCA-3′; mouse IL-6, sense 5′-CACT TCACAAGTCGGAGGCTTA-3′, antisense 5′-GCAAGTGCATCATC GTTGTTC-3′; mouse IL-23, sense 5′-TGGCATCGAGAAACTGTGAG A-3′, antisense 5′-TCAGTTCGTATTGGTAGTCCTGTTA-3′; and mouse β-actin, sense AGAGGGAAATCGTGCGTGAC-3′, antisense 5′-CAATAGTGATGACCTGGCCGT-3′.

Immunoassays of cytokines and anti-type II collagen Ab

The concentrations of mIL-6, mTNF-α, and mIL-17A in mouse sera and culture supernatants were measured by sandwich ELISA, according to the manufacturer's protocol (BD Pharmingen). An automatic microplate reader (Bio-Rad 550) was used to measure the OD. Mouse serum IgG anti-type II collagen Ab titer was measured, as previously described (35).

Isolation of cartilage

Murine articular cartilage was isolated from patellae, as described previously (36). In brief, patellae were decalcified in 3.5% EDTA for 4 h at 4°C, when the whole cartilage layer was stripped off. Because old cartilage is more calcified, decalcification of the patellae of old mice (>3 mo) was performed overnight at 4°C.

Cell purification

Briefly, the arthritic paws of the CIA mice were cut into pieces, digested with collagenase type IV (Sigma-Aldrich), and stained with mAbs (Fc blocking with anti-mouse CD16/CD32 mAb, and staining with anti-mouse CD3-PE mAb, anti-mouse CD4-allophycocyanin mAb, anti-mouse CD11b-FITC mAb, anti-mouse CD11c-FITC mAb, anti-mouse CD19-FITC mAb, biotinylated anti-mouse I-A/I-E (MHC class II) mAb, and streptavidin PE Ab that were obtained from BD Pharmingen). Cell sorting of a specific cell population was performed with a FACSVantage flow cytometer (BD Biosciences).

Intracellular cytokine staining and flow cytometry

IL-17 family expressions of Ba/F3 cells transduced with each of IL-17 family members were examined using intracellular cytokine staining. Ba/F3 cells were infected with the retroviral supernatants in the presence of 10 μg/ml polybrene (Sigma-Aldrich) for 120 min. These cells were stained with anti-mouse IL-17A mAb conjugated to PE (BD Pharmingen), biotinylated anti-mouse IL-17B polyclonal Ab (R&D Systems), anti-mouse IL-17C polyclonal Ab (R&D Systems), and anti-mouse IL-17F mAb (R&D Systems), respectively. Bovine anti-goat IgG-PE (Santa Cruz Biotechnology) and $F(ab')_2$ goat anti-rat IgG PE (Serotec) were used as secondary reagents for IL-17C and IL-17F staining, respectively. Cell fixation and permeabilization were performed using Cytofix/Cytoperm reagent (BD Pharmingen), according to the manufacturer's protocol (BD Pharmingen), and analyzed by flow cytometry. Splenocytes isolated from BM chimeric mice of IL-17A were also stained with anti-mouse IL-17A mAb in the same way.

Anti-IL-17B Ab treatment in CIA mice

CIA was induced in DBA/1J mice, as described above. Mice exhibited the first clinical signs of arthritis (arthritis score between 1 and 2) and were injected i.p. with 100 μg of polyclonal anti-mouse IL-17B Abs (R&D Systems). PBS was i.p. injected as a control. Arthritis was assessed using a scoring system, as described above. Mice were sacrificed at 10 days after the onset of arthritis, and the paws were removed. Joint pathology was evaluated on decalcified H&E-stained sections.

Histopathology

The tarsal joints of sacrificed CIA mice were embedded in paraffin wax after 10% formaldehyde fixation and decalcification. The sections were stained with H&E. Synovial tissues were graded by mononuclear cell infiltration and pannus invasion, as described previously (37).

Statistical analysis

Data are expressed as the means ± SD. All results were obtained by at least three independent experiments. Statistical significance was determined by the Mann-Whitney U test and unpaired Student's t tests. A value of $p < 0.05$ was considered statistically significant.

Results

IL-17 family genes (IL-17A, IL-17B, IL-17C, and IL-17F) were highly expressed in the arthritic paws of CIA mice

First, we examined the expressions of IL-17 family members and IL-17Rs in the arthritic paws of CIA mice by quantitative PCR. The mRNA expressions of all IL-17 family genes examined (IL-17A, IL-17B, IL-17C, and IL-17F) were highly elevated in the arthritic paws compared with the controls. In accordance with previous report of high in vivo expression of IL-17R in RA (38), mRNA expressions of IL-17Rs (IL-17R and IL-17Rh1) were also elevated (Fig. 1*A*). As expected, the mRNA expressions of inflammatory cytokines (TNF-α, IL-1β, IL-6, and IL-23) were also elevated in the arthritic paws compared with controls (Fig. 1*B*).

We next examined cell populations in the arthritic paws of CIA mice that express IL-17 family members. Subpopulations of the cells were sorted with various cell surface markers using a flow cytometer. As expected, $CD4^+$ T cells expressed IL-17A and IL-17F significantly. IL-17B was expressed exclusively in the inflammatory cartilage of CIA mice. In contrast, IL-17C was expressed in a broad range of cells, i.e., $CD4^+$ T cells, $CD11b^+$ MHC class II^+ macrophages, and $CD11c^+$ MHC class II^+ dendritic cells (Fig. 1*C*). These results suggested that $CD4^+$ T cells mainly express IL-17 family members, especially IL-17A, IL-17C, and IL-17F, at the inflammatory site.

IL-17 family induced several proinflammatory cytokines

We next investigated whether IL-17 family members have an influence on mouse fibroblast cell lines and mouse peritoneal macrophages. Cells of the mouse fibroblast line *3T3* were cultured with each of the IL-17 family members (50 ng/ml), and cytokine expression was examined after 24 h of incubation. IL-17A induced IL-1β and IL-6 expressions, as previously reported (2). Moreover, IL-17B, IL-17C, and IL-17F also induced IL-1β expression in *3T3* (Fig. 2*A*).

To examine the effects of IL-17 family members on mouse macrophages, thioglycolate-elicited PECs were isolated and cultured with each of the IL-17 family members (50 ng/ml). IL-17A induced IL-1β, IL-6, and IL-23 expressions in PECs. Interestingly, IL-17B also induced IL-1β, IL-6, and IL-23 expressions. Moreover, IL-17C induced IL-1β and IL-23 expressions in PECs (Fig. 2*B*). In addition, PECs stimulated with every IL-17 family member produced significantly increased amount of TNF-α protein compared with the control, and PECs stimulated with IL-17A and IL-17B produced significantly increased amount of IL-6 protein (Fig. 2*C*). These results suggested that IL-17A, IL-17B, IL-17C, and IL-17F stimulate fibroblasts and macrophages to produce inflammatory cytokines.



FIGURE 1. The expression of IL-17 family members and IL-17R genes in the arthritic paws of CIA mice. *A*, The expressions of IL-17 family genes and IL-17R genes were examined in the arthritic paws of CIA mice (■; $n = 3$) and in control mice (□; $n = 3$) by quantitative PCR. *B*, The expressions of inflammatory cytokines. *C*, The expressions of IL-17 family members in the sorted cell populations of the arthritic paws of CIA mice. The data are representative of three independent experiments.

Exacerbation of CIA by transfer of IL-17 family-transduced CD4$^+$ T cells

Because IL-17B and IL-17C induce the expression of inflammatory cytokines in fibroblasts and macrophages, we hypothesized that IL-17B and IL-17C have an effect on the process of arthritis. We subcloned cDNA fragment of mIL-17A, mIL-17B, mIL-17C, or mIL-17F to pMIG retrovirus vector. These vectors were retrovirally transduced to Ba/F3 cells, and protein expressions of IL-17 family members were confirmed with intracellular staining of each IL-17 family cytokine (Fig. 3*A*).

To examine the proinflammatory effects of the IL-17 family in vivo, we retrovirally transduced the IL-17 family genes to CD4$^+$ T cells. The transduction efficiencies were ~30% on average (Fig. 3*B*). These IL-17 family-transduced CD4$^+$ T cells were adoptively transferred to BCII-immunized DBA1 mice before the onset of arthritis. They exacerbated the progression of arthritis, as observed by the arthritis score (Fig. 3, *C* and *D*). The IL-17 family member-transduced CD4$^+$ T cells had no significant effect on the serum levels of anti-BCII IgG Abs at 14 days after the onset of CIA (data not shown). These results



FIGURE 2. The proinflammatory effects of IL-17 family members on mouse fibroblasts and macrophages. *A*, Relative expression of the cytokine genes in *3T3* cell. The mouse fibroblast cell line *3T3* was cultured with each of mIL-17A, mIL-17B, mIL-17C, or mIL-17F for 24 h, and the expressions of inflammatory cytokines were measured by quantitative PCR. *B*, Relative expression of the cytokine genes in mouse thioglycolate-elicited PECs. PECs were cultured with each of mIL-17A, mIL-17B, mIL-17C, or mIL-17F for 24 h, and the expressions of inflammatory cytokines were measured by quantitative PCR. *C*, The secreted IL-6 and TNF-α levels in the supernatants of *3T3* and PECs were measured by ELISA. Error bars indicate ± SD. The data are representative of three independent experiments. Significance of differences between control (medium) and each IL-17 family was determined; *, $p < 0.05$.



FIGURE 3. The effects of transfer of IL-17 family-transduced CD4$^+$ T cells on CIA. *A*, Intracellular IL-17 family expressions in Ba/F3 cells retrovirally transduced with each IL-17 family member. GFP-gated IL-17 family-transduced (mIL-17A, mIL-17B, mIL-17C, or mIL-17F) Ba/F3 cells were analyzed for IL-17A, IL-17B, IL-17C, or IL-17F expression compared with GFP-gated empty vector (pMIG)-transduced Ba/F3 cells. *B*, Representative FACS analysis of IL-17 family-transduced CD4$^+$ T cells was shown. Numbers in dot plots indicate the percentage of GFP$^+$ CD4$^+$ and GFP$^-$ CD4$^+$ cells, and the percentages of the GFP$^+$ cells within total CD4$^+$ cells were shown below. *C* and *D*, CD4$^+$ T cells transduced with each of IL-17 family genes were transferred to collagen-immunized mice before the onset of arthritis (day 23). The incidence of arthritis (*C*) and the progression of arthritis scores (*D*) are shown. Values are the mean of arthritis score (n = 20 mice per group). Significance of differences between control (pMIG) and each IL-17 family-transduced mice was determined; **, $p < 0.005$; *, $p < 0.05$.

indicated that the effect of IL-17 family members on the progression of arthritis was not associated with the elevations of anti-BCII Abs.

IL-17 family BM chimeric mice exhibited high arthritis scores upon CIA induction

To examine the proinflammatory effect of constitutively expressed IL-17 family members, we established IL-17 family BM chimeric mice by transfer of gene-transduced BM cells to lethally irradiated mice. In a previous study, the attempt to generate IL-17A-overexpressing mice with a conventional transgenic approach was unsuccessful because these mice were embryonic lethal (39). In accordance with the previous report, mice that expressed IL-17A with high efficiency (i.e., for which the percentage of GFP$^+$ cells in the spleen was >50%) became gaunt and died within 1 mo after BM transplantation (data not shown). When the percentage of GFP$^+$ cells in the spleen was 5–15%, the mice appeared to be healthy for several months. We therefore used BM chimeric mice that expressed IL-17 family genes in ~5–15% of spleen cells. Eight weeks after the BM transplantation, mIL-17A was readily detected by intracellular cytokine staining (Fig. 4*A*). Moreover, the serum concentration of mIL-17A was significantly elevated in these mice (Fig. 4*B*). Therefore, the BM chimeric mice were successfully allowed to express the transduced cytokines systemically. Then we immunized these mice with BCII 8 wk after BM transplantation. BM chimeric mice of IL-17A and IL-17F exhibited early onset and high arthritis scores upon CIA induction (Fig. 5, *A* and *B*). BM chimeric mice of IL-17B and IL-17C clearly exacerbated arthritis, as assessed by the arthritis score. In contrast, BM chimeric mice of IL-17B and IL-17C did not result in significant differences in the onset of disease (Fig. 5, *C* and *D*). BM expression of IL-17 family member did not affect the anti-BCII Ab responses at 14 days after the onset of CIA (data not shown). These results indicated that the effect of IL-17 family members on the exacerbation of arthritis was not associated with the responses of anti-BCII Abs.



FIGURE 4. Generation of IL-17 family chimeric mice by BM transplantation of gene-transduced BM cells. Each of IL-17 family genes was transduced to BM cells with retrovirus vector and transferred to lethally irradiated mice. *A*, The intracellular expression of IL-17A protein in the spleen of IL-17A BM chimeric mice 8 wk after BM transplantation. The percentage of GFP$^+$ cells expressing IL-17A is indicated. The data are representative of three independent experiments. *B*, The concentration of IL-17A protein in the serum of IL-17A BM chimeric mice (n = 6) and control mice (pMIG BM chimeric mice) (n = 6). The levels of IL-17A were measured by ELISA.



FIGURE 5. Incidence of CIA and arthritis scores in IL-17 family BM chimeric mice. Incidence of CIA and arthritis scores in IL-17A and IL-17F BM chimeric mice (*A* and *B*), and in IL-17B and IL-17C BM chimeric mice (*C* and *D*). Mice were immunized with BCII 8 wk after the BM transplantation. Values are the mean of experiments for IL-17A and IL-17F BM chimeric mice (n = 20 per group) and experiments for IL-17B and IL-17C BM chimeric mice (n = 30 per group). Significance of differences between control (pMIG) and each IL-17 family BM chimeric mice was determined; **, $p < 0.005$; *, $p < 0.05$. *E*, The mRNA expression of inflammatory cytokines in the spleen of BM chimeric mice of IL-17B and IL-17C, which were immunized with BCII (■; n = 15 per group) or nonimmunized controls (□; n = 6 per group). Significance of differences between control (pMIG) and each IL-17 family BM chimeric mice was determined; **, $p < 0.005$; *, $p < 0.05$. *F*, The secreted TNF-α and IL-6 levels in the serum of IL-17 family BM chimeric mice that were immunized with BCII (■; n = 15) or nonimmunized controls (□; n = 6). Significance of differences between control (pMIG) and each IL-17 family BM chimeric mice was determined; **, $p < 0.005$; *, $p < 0.05$.

We next examined the alterations of inflammatory cytokine production in these BM chimeric mice. Interestingly, nonimmunized IL-17C BM chimeric mice showed increased mRNA expression of TNF-α in the spleen compared with controls (Fig. 5*E*). Moreover, in the spleen of BCII-immunized IL-17C BM chimeric mice, the mRNA expressions of TNF-α, IL-6, and IL-23 were up-regulated. In contrast, BCII-immunized IL-17B BM chimeric mice showed increased mRNA expression of IL-6 in the spleen compared with controls (Fig. 5*E*). When we examined the concentrations of TNF-α and IL-6 protein in the sera of IL-17 family BM chimeric mice, the BCII-immunized IL-17B and IL-17C BM chimeric mice showed increased TNF-α concentration in the sera. And the BCII-immunized IL-17A and IL-17B BM chimeric mice showed increased IL-6 production in the sera (Fig. 5*F*). These results suggested that IL-17B and IL-17C enhanced inflammation in this mouse model of arthritis by increased inflammatory cytokine production.

Neutralization of IL-17B significantly suppressed the progression of arthritis

As shown in Fig. 5, we found that IL-17B exacerbated the progression of CIA as well as IL-17A with the method of retrovirus-mediated BM chimeric mice. Regarding IL-17A, neutralizing Abs against IL-17A have been previously shown to be effective in the treatment of CIA (8). We examined the effect of IL-17B blockade in CIA mice. CIA mice were systemically treated with polyclonal anti-mouse IL-17B Abs immediately after the first signs of arthritis. Neutralization of IL-17B significantly suppressed the progression of CIA compared with the controls (Fig. 6*A*). Moreover, histological analysis revealed significant reduction of cell infiltration



FIGURE 6. Effect of anti-IL-17B Ab treatment in CIA mice. *A*, CIA mice received i.p. injection of anti-mouse IL-17B Abs after the first clinical signs of arthritis (arthritis score between 1 and 2). As a control, PBS was injected. The arthritis score was shown. *B*, Histological score of the inflammatory joints of CIA mice treated with anti-IL-17B Abs was evaluated at 10 days after the onset of arthritis. Cellular infiltration and pannus invasion were graded in all four paws of the mice. Values are the mean of arthritis scores for anti-IL-17B Ab-treated mice and control mice (n = 5 per group). Significance of differences between control and anti-IL-17B Ab-treated mice was shown.

and pannus invasion in the anti-IL-17B Ab-treated mice (Fig. 6*B*). These results indicated that IL-17B was associated with the progression of arthritis in CIA mice.

Discussion

RA is considered to be an autoimmune disease, and is characterized by sustained inflammation of the joints and destruction of cartilage and bone. Several inflammatory cytokines are known to mediate the pathogenesis of arthritis, and TNF-α and IL-6 are the most important cytokines in the pathogenesis of RA. IL-17A, IL-17B, IL-17C, and IL-17F have the capacity to induce TNF-α production in PECs in vitro. In vivo, the mRNA expression of TNF-α was spontaneously increased in the spleen of IL-17C BM chimeric mice. Moreover, TNF-α productions in the sera of BCII-immunized IL-17B and IL-17C BM chimeric mice were up-regulated. Although IL-17A induced TNF-α production in PECs. IL-17A BM chimeric mice did not show up-regulated production of TNF-α. This result is consistent with previous observation in THP-1 cell line that IL-17B and IL-17C stimulated the release of TNF-α, whereas IL-17A has only a weak effect on TNF-α (17). In contrast to IL-17B and IL-17C, IL-17A may not be directly associated with TNF-α production in vivo. Moreover, the mRNA expression in the spleen and serum concentration of IL-6 were significantly up-regulated in IL-17B BM chimeric mice that were immunized with BCII. These results showed the close association of IL-17B and IL-17C with TNF-α and IL-6 in vivo and clearly suggested the importance of IL-17B and IL-17C in the pathogenesis of RA.

To date, the cell sources of IL-17B and IL-17C have not been identified. In this study, we showed that IL-17B was expressed in the inflammatory cartilage of CIA mice, whereas IL-17C was expressed in a broad range of cells, i.e., $CD4^+$ T cells, $CD11b^+$ MHC class II^+ macrophages, and $CD11c^+$ MHC class II^+ dendritic cells. IL-17A and IL-17F were expressed in $CD4^+$ T cells, as expected. These results suggested that $CD4^+$ T cells are involved in the expression of IL-17 family members, especially IL-17A, IL-17C, and IL-17F, at the inflammatory site. Although we did not detect a unique cell source of IL-17C, the arthritis-promoting effect of IL-17C-transduced $CD4^+$ T cells suggests the importance of IL-17C expressed in $CD4^+$ T cells.

In our in vivo analysis, we observed arthritis-promoting effects of the IL-17 family members. As shown in Fig. 3, the transfer of mIL-17A-, mIL-17B-, mIL-17C-, and mIL-17F-transduced $CD4^+$ T cells evidently exacerbated arthritis as assessed by the arthritis score. This effect was also confirmed in the CIA of the mIL-17A, mIL-17B, mIL-17C, and mIL-17F BM chimeric mice. The arthritis-promoting effect of IL-17A was previously reported in a study using adenovirus vector (5, 40). In contrast to IL-17A, which hastened the onset of arthritis, IL-17B and IL-17C did not affect the onset of arthritis evidently. This fact suggests that IL-17B and IL-17C affect arthritis rather in the effector phase. To our knowledge, this is the first observation of an in vivo arthritis-promoting effect of IL-17B and IL-17C.

Blockade of IL-17A has recently been shown to be effective in the treatment of CIA (8). In the present study, we have demonstrated the therapeutic potential of IL-17B blockade after the onset of CIA. Because blockade of TNF-α or IL-1β is not always effective in RA patients, blockade of additional cytokine might be a useful therapeutic option. Therefore, our data strongly suggest that IL-17B as well as IL-17A could be an important target for the treatment of inflammatory arthritis.

In a recent study, the combination of IL-6 and TGF-β was reported to strongly induce IL-17A production in Th17 cells (41). Moreover, it was recently recognized that IL-23 contributes to the expansion of autoreactive IL-17A-producing T cells and promotes chronic inflammation dominated by IL-17A, IL-6, IL-8, and TNF-α (14, 42). Thus, IL-17B and IL-17C may exacerbate arthritis via IL-6- and IL-23-mediated promotion of IL-17A production. However, the possibility that IL-17B and IL-17C exert a cooperative proinflammatory response together with IL-17A and IL-17F in arthritis by regulating the release of cytokines such as IL-6, IL-1β, and IL-23 still remains to be examined.

IL-17F has the highest homology with IL-17A and, like IL-17A, is produced by activated T cells. IL-17F appears to have an effect similar to that of IL-17A on cartilage proteoglycan release and inhibition of new cartilage matrix synthesis (11). Although IL-17F is thought to contribute to the pathology of inflammatory disorders such as RA, the in vivo effect of IL-17F on arthritis was not elucidated. In this study, we found that transduction of BM-expressed IL-17F resulted in both an earlier onset and a subsequent aggravation of arthritis.

We also found that the mRNA expression of all IL-17 family and IL-17R genes examined (mIL-17A, mIL-17B, mIL-17C, mIL-17F, mIL-17R, and mIL-17Rh1) was elevated in the arthritic paws of CIA mice compared with the paws of the control mice. The receptor for IL-17A is IL-17R (also named IL-17AR), which is extensively expressed in various tissues or cells tested, in contrast to the exclusive expression of IL-17A in activated T cells. Recently, IL-17R signaling has been suggested to play a crucial role in driving the synovial expression of proinflammatory and catabolic mediators, such as IL-1, IL-6, matrix metalloproteinase

(MMP)-3, MMP-9, and MMP-13, in streptococcal cell wall-induced arthritis (43). IL-17R-deficient (IL-17R$^{-/-}$) mice that were locally injected five times with streptococcal cell wall fragments into the knee joints showed a significant reduction of joint thickness and cartilage damage that was accompanied by reduced synovial expression of IL-1, IL-6, and the MMPs 3, 9, and 13 compared with arthritic wild-type mice. Therefore, these results indicate the critical role of IL-17R signaling during progression from an acute, macrophage-driven joint inflammation to a chronic, cartilage-destructive, T cell-mediated synovitis. There are four additional receptor-like molecules that share homology to IL-17R, i.e., IL-17Rh1 (also named IL-17RB or IL-17BR), IL-17RL (also named IL-17RC), IL-17RD, and IL-17RE. IL-17Rh1 was shown to bind to IL-17B, but with higher affinity to IL-17E (11, 12).

Although IL-17A transgenic mice have been reported to be embryonic lethal (39), we established BM-overexpressing mice that constitutively expressed IL-17A. The adequate control of the expression level was critically important. In our experiment, the serum concentration of IL-17A was elevated to ~600 pg/ml in IL-17A BM chimeric mice. This serum concentration of IL-17A was similar to those in patients with inflammatory diseases such as RA, inflammatory bowel diseases, familial Mediterranean fever, and the acute stage of Kawasaki disease (3, 44–46). Therefore, our BM chimeric mice approach may be useful to elucidate the physiological role of inflammatory cytokines that show lethal phenotypes in the conventional gene-transgenic technique.

In conclusion, we found that IL-17 family genes were up-regulated in association with their receptors in CIA. Each of the IL-17 family members clearly exacerbated the progression of CIA with the method of retrovirus-mediated BM chimeric mice. IL-17B and IL-17C have the capacity to exacerbate inflammatory arthritis in association with increased TNF-α and IL-6 productions from macrophages. Moreover, neutralization of IL-17B significantly suppressed the progression of arthritis and bone destruction in CIA mice. Therefore, our results suggest that not only IL-17A, but also the IL-17 family members IL-17B, IL-17C, and IL-17F play an important role in the pathogenesis of inflammatory arthritis and should be a new therapeutic target of arthritis.

Acknowledgments

We are grateful to Yayoi Tsukahara and Kayako Watada for their excellent technical assistance.

Disclosures

The authors have no financial conflict of interest.

References

1. Yao, Z., W. C. Fanslow, M. F. Seldin, A. M. Rousseau, S. L. Painter, M. R. Comeau, J. I. Cohen, and M. K. Spriggs. 1995. Herpesvirus Saimiri encodes a new cytokine: IL-17, which binds to a novel cytokine receptor. *Immunity* 3: 811–821.
2. Yao, Z., S. L. Painter, W. C. Fanslow, D. Ulrich, B. M. Macduff, M. K. Spriggs, and R. J. Armitage. 1995. Human IL-17: a novel cytokine derived from T cells. *J. Immunol.* 155: 5483–5486.
3. Ziolkowska, M., A. Koc, G. Luszczykiewicz, K. Ksiezopolska-Pietrzak, E. Klimczak, H. Chwalinska-Sadowska, and W. Maslinski. 2000. High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism. *J. Immunol.* 164: 2832–2838.
4. Jovanovic, D. V., J. A. Di Battista, J. Martel-Pelletier, F. C. Jolicoeur, Y. He, M. Zhang, F. Mineau, and J. P. Pelletier. 1998. IL-17 stimulates the production and expression of proinflammatory cytokines IL-β and TNF-α, by human macrophages. *J. Immunol.* 160: 3513–3521.
5. Chabaud, M., F. Fossiez, J. L. Taupin, and P. Miossec. 1998. Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines. *J. Immunol.* 161: 409–414.
6. Katz, Y., O. Nadiv, and Y. Beer. 2001. Interleukin-17 enhances tumor necrosis factor α-induced synthesis of interleukins 1, 6, and 8 in skin and synovial fibroblasts: a possible role as a "fine-tuning cytokine" in inflammation processes. *Arthritis Rheum.* 44: 2176–2184.
7. Lubberts, E., L. A. Joosten, B. Oppers, L. van den Bersselaar, C. J. Coenen-de Roo, J. K. Kolls, P. Schwarzenberger, F. A. van de Loo, and W. B. van den Berg. 2001. IL-1-independent role of IL-17 in synovial inflammation and joint destruction during collagen-induced arthritis. *J. Immunol.* 167: 1004–1013.
8. Lubberts, E., M. I. Koenders, B. Oppers-Walgreen, L. van den Bersselaar, C. J. Coenen-de Roo, L. A. Joosten, and W. B. van den Berg. 2004. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. *Arthritis Rheum.* 50: 650–659.
9. Nakae, S., S. Saijo, R. Horai, K. Sudo, S. Mori, and Y. Iwakura. 2003. IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist. *Proc. Natl. Acad. Sci. USA* 100: 5986–5990.
10. Koenders, M. I., E. Lubberts, F. A. van de Loo, B. Oppers-Walgreen, L. van den Bersselaar, M. M. Helsen, J. K. Kolls, F. E. Di Padova, L. A. Joosten, and W. B. van den Berg. 2006. Interleukin-17 acts independently of TNF-α under arthritic conditions. *J. Immunol.* 176: 6262–6269.
11. Moseley, T. A., D. R. Haudenschild, L. Rose, and A. H. Reddi. 2003. Interleukin-17 family and IL-17 receptors. *Cytokine Growth Factor Rev.* 14: 155–174.
12. Kolls, J. K., and A. Linden. 2004. Interleukin-17 family members and inflammation. *Immunity* 21: 467–476.
13. Starnes, T., M. J. Robertson, G. Sledge, S. Kelich, H. Nakshatri, H. E. Broxmeyer, and R. Hromas. 2001. Cutting edge: IL-17F, a novel cytokine selectively expressed in activated T cells and monocytes, regulates angiogenesis and endothelial cell cytokine production. *J. Immunol.* 167: 4137–4140.
14. Aggarwal, S., N. Ghilardi, M. H. Xie, F. J. de Sauvage, and A. L. Gurney. 2003. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. *J. Biol. Chem.* 278: 1910–1914.
15. Happel, K. I., P. J. Dubin, M. Zheng, N. Ghilardi, C. Lockhart, L. J. Quinton, A. R. Odden, J. E. Shellito, G. J. Bagby, S. Nelson, and J. K. Kolls. 2005. Divergent roles of IL-23 and IL-12 in host defense against *Klebsiella pneumoniae*. *J. Exp. Med.* 202: 761–769.
16. Shi, Y., S. J. Ullrich, J. Zhang, K. Connolly, K. J. Grzegorzewski, M. C. Barber, W. Wang, K. Wathen, V. Hodge, C. L. Fisher, et al. 2000. A novel cytokine receptor-ligand pair: identification, molecular characterization, and in vivo immunomodulatory activity. *J. Biol. Chem.* 275: 19167–19176.
17. Li, H., J. Chen, A. Huang, J. Stinson, S. Heldens, J. Foster, P. Dowd, A. L. Gurney, and W. I. Wood. 2000. Cloning and characterization of IL-17B and IL-17C, two new members of the IL-17 cytokine family. *Proc. Natl. Acad. Sci. USA* 97: 773–778.
18. Hurst, S. D., T. Muchamuel, D. M. Gorman, J. M. Gilbert, T. Clifford, S. Kwan, S. Menon, B. Seymour, C. Jackson, T. T. Kung, et al. 2002. New IL-17 family members promote Th1 or Th2 responses in the lung: in vivo function of the novel cytokine IL-25. *J. Immunol.* 169: 443–453.
19. Chabaud, M., J. M. Durand, N. Buchs, F. Fossiez, G. Page, L. Frappart, and P. Miossec. 1999. Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. *Arthritis Rheum.* 42: 963–970.
20. Hymowitz, S. G., E. H. Filvaroff, J. P. Yin, J. Lee, L. Cai, P. Risser, M. Maruoka, W. Mao, J. Foster, R. F. Kelley, et al. 2001. IL-17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL-17F, and implications for receptor binding. *EMBO J.* 20: 5332–5341.
21. Hwang, S. Y., and H. Y. Kim. 2005. Expression of IL-17 homologs and their receptors in the synovial cells of rheumatoid arthritis patients. *Mol. Cell* 19: 180–184.
22. Nasu, K., H. Kohsaka, Y. Nonomura, Y. Terada, H. Ito, K. Hirokawa, and N. Miyasaka. 2000. Adenoviral transfer of cyclin-dependent kinase inhibitor genes suppresses collagen-induced arthritis in mice. *J. Immunol.* 165: 7246–7252.
23. Trentham, D. E., A. S. Townes, and A. H. Kang. 1977. Autoimmunity to type II collagen an experimental model of arthritis. *J. Exp. Med.* 146: 857–868.
24. Stuart, J. M., A. S. Townes, and A. H. Kang. 1982. Nature and specificity of the immune response to collagen in type II collagen-induced arthritis in mice. *J. Clin. Invest.* 69: 673–683.
25. Gerlag, D. M., L. Ransone, P. P. Tak, Z. Han, M. Palanki, M. S. Barbosa, D. Boyle, A. M. Manning, and G. S. Firestein. 2000. The effect of a T cell-specific NF-κB inhibitor on in vitro cytokine production and collagen-induced arthritis. *J. Immunol.* 165: 1652–1658.
26. Nanki, T., Y. Urasaki, T. Imai, M. Nishimura, K. Muramoto, T. Kubota, and N. Miyasaka. 2004. Inhibition of fractalkine ameliorates murine collagen-induced arthritis. *J. Immunol.* 173: 7010–7016.
27. Unkeless, J. C., S. Gordon, and E. Reich. 1974. Secretion of plasminogen activator by stimulated macrophages. *J. Exp. Med.* 139: 834–850.
28. Cheng, E. H., M. C. Wei, S. Weiler, R. A. Flavell, T. W. Mak, T. Lindsten, and S. J. Korsmeyer. 2001. BCL-2. Bcl-x_L sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. *Mol. Cell* 8: 705–711.
29. Morita, S., T. Kojima, and T. Kitamura. 2000. Plat-E: an efficient and stable system for transient packaging of retroviruses. *Gene Ther.* 7: 1063–1066.
30. Fujio, K., Y. Misaki, K. Setoguchi, S. Morita, K. Kawahata, I. Kato, T. Nosaka, K. Yamamoto, and T. Kitamura. 2000. Functional reconstitution of class II MHC-restricted T cell immunity mediated by retroviral transfer of the $\alpha\beta$ TCR complex. *J. Immunol.* 165: 528–532.
31. Fujio, K., A. Okamoto, H. Tahara, M. Abe, Y. Jiang, T. Kitamura, S. Hirose, and K. Yamamoto. 2004. Nucleosome-specific regulatory T cells engineered by triple gene transfer suppress a systemic autoimmune disease. *J. Immunol.* 173: 2118–2125.

32. McGaha, T. L., B. Sorrentino, and J. V. Ravetch. 2005. Restoration of tolerance in lupus by targeted inhibitory receptor expression. *Science* 307: 590–593.
33. Livak, K. J., and T. D. Schmittgen. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the $2(-\delta\delta C_T)$ method. *Methods* 25: 402–408.
34. Ferreira, I. D., V. E. Rosario, and P. V. Cravo. 2006. Real-time quantitative PCR with SYBR Green I detection for estimating copy numbers of nine drug resistance candidate genes in *Plasmodium falciparum*. *Malar J.* 5: 1.
35. Corthay, A., A. Johansson, M. Vestberg, and R. Holmdahl. 1999. Collagen-induced arthritis development requires $\alpha\beta$ T cells but not $\gamma\delta$ T cells: studies with T cell-deficient (TCR mutant) mice. *Int. Immunol.* 11: 1065–1073.
36. Glansbeek, H. L., P. M. van der Kraan, F. P. Lafeber, E. L. Vitters, and W. B. van den Berg. 1997. Species-specific expression of type II TGF-β receptor isoforms by articular chondrocytes: effect of proteoglycan depletion and aging. *Cytokine* 9: 347–351.
37. Taniguchi, K., H. Kohsaka, N. Inoue, Y. Terada, H. Ito, K. Hirokawa, and N. Miyasaka. 1999. Induction of the p16INK4a senescence gene as a new therapeutic strategy for the treatment of rheumatoid arthritis. *Nat. Med.* 5: 760–767.
38. Honorati, M. C., R. Meliconi, L. Pulsatelli, S. Cane, L. Frizziero, and A. Facchini. 2001. High in vivo expression of interleukin-17 receptor in synovial endothelial cells and chondrocytes from arthritis patients. *Rheumatology* 40: 522–527.
39. Schwarzenberger, P., V. La Russa, A. Miller, P. Ye, W. Huang, A. Zieske, S. Nelson, G. J. Bagby, D. Stoltz, R. L. Mynatt, et al. 1998. IL-17 stimulates granulopoiesis in mice: use of an alternate, novel gene therapy-derived method for in vivo evaluation of cytokines. *J. Immunol.* 161: 6383–6389.
40. Lubberts, E., L. van den Bersselaar, B. Oppers-Walgreen, P. Schwarzenberger, C. J. Coenen-de Roo, J. K. Kolls, L. A. Joosten, and W. B. van den Berg. 2003. IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-κB ligand/osteoprotegerin balance. *J. Immunol.* 170: 2655–2662.
41. Mangan, P. R., L. E. Harrington, D. B. O'Quinn, W. S. Helms, D. C. Bullard, C. O. Elson, R. D. Hatton, S. M. Wahl, T. R. Schoeb, and C. T. Weaver. 2006. Transforming growth factor-β induces development of the T_H17 lineage. *Nature* 441: 231–234.
42. Hunter, C. A. 2005. New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. *Nat. Rev. Immunol.* 5: 521–531.
43. Koenders, M. I., J. K. Kolls, B. Oppers-Walgreen, L. van den Bersselaar, L. A. Joosten, J. R. Schurr, P. Schwarzenberger, W. B. van den Berg, and E. Lubberts. 2005. Interleukin-17 receptor deficiency results in impaired synovial expression of interleukin-1 and matrix metalloproteinases 3, 9, and 13 and prevents cartilage destruction during chronic reactivated streptococcal cell wall-induced arthritis. *Arthritis Rheum.* 52: 3239–3247.
44. Fujino, S., A. Andoh, S. Bamba, A. Ogawa, K. Hata, Y. Araki, T. Bamba, and Y. Fujiyama. 2003. Increased expression of interleukin 17 in inflammatory bowel disease. *Gut* 52: 65–70.
45. Haznedaroglu, S., M. A. Ozturk, B. Sancak, B. Goker, A. M. Onat, N. Bukan, I. Ertenli, S. Kiraz, and M. Calguneri. 2005. Serum interleukin 17 and interleukin 18 levels in familial Mediterranean fever. *Clin. Exp. Rheumatol.* 23: S77–S80.
46. Sohn, M. H., S. Y. Noh, W. Chang, K. M. Shin, and D. S. Kim. 2003. Circulating interleukin 17 is increased in the acute stage of Kawasaki disease. *Scand. J. Rheumatol.* 32: 364–366.

T Cell Receptor Gene Therapy for Autoimmune Diseases

KEISHI FUJIO, TOMOHISA OKAMURA, AKIKO OKAMOTO, AND KAZUHIKO YAMAMOTO

Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

ABSTRACT: **The current quality of autoimmune disease treatments is not satisfactory in regard to efficacy and safety. Antigen-specific immunotherapy is a future therapy that could achieve maximal efficacy with minimal adverse effects. T cells are essential components in antigen-specific immunity. However, we do not have a sufficient strategy for manipulating antigen-specific T cells. We propose that T cell receptor (TCR) gene transfer is a hopeful approach for antigen-specific immunotherapy. We confirmed the efficacy of TCR gene therapy in animal models of systemic autoimmune disease and arthritis. In lupus-prone NZB/W F1 mice, nucleosome-specific TCR and CTLA4Ig transduced cells suppressed autoantibody production and nephritis development. In the therapeutic experiment of collagen-induced arthritis (CIA), arthritis-related TCRs were isolated from single T cells accumulating in the arthritis site. Arthritis-related TCR and TNFRIg transduced cells or TCR and Foxp3 transduced cells suppressed arthritis progression and bone destruction. Therefore, engineered antigen-specific cells manipulated to express appropriate functional genes could be applied to specific immunotherapy.**

KEYWORDS: **autoimmune diseases; antigen-specific T cells; gene transfer; T cell receptor**

INTRODUCTION

Rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, and type 1 diabetes are regarded as diseases associated with autoimmunity. These autoimmune diseases are relatively common disorders affecting about 5% of the population, predominantly women.[1] Current treatment of the autoimmune diseases is composed of nonspecific immunosuppressive drugs, such as corticosteroids and cytotoxic reagents. Though nonspecific immunosuppressive therapy has improved clinical outcome of patients in autoimmune diseases, it is

Address for correspondence: Keishi Fujio, Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113, Japan. Voice: +81-3-3815-5411; fax: +81-3-3815-5954.
kfujio-tky@umin.ac.jp

Ann. N.Y. Acad. Sci. 1110: 222–232 (2007).
doi: 10.1196/annals.1423.024